The predicted effect of changes in cervical screening practice in the UK: results from a modelling study

被引:69
作者
Canfell, K
Barnabas, R
Patnick, J
Beral, V
机构
[1] Univ Oxford, Radcliffe Infirm, Canc Res UK Epidemiol Unit, Oxford OX2 6HE, England
[2] NHS Canc Screening Programmes, Sheffield S11 9PS, S Yorkshire, England
关键词
cervix neoplasms; mass screening; models; biological;
D O I
10.1038/sj.bjc.6602002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In 2003, the National Health Service Cervical Screening Programme (NHSCSP) announced that its screening interval would be reduced to 3 years in women aged 25 - 49 and fixed at 5 years in those aged 50 - 64, and that women under 25 years will no longer be invited for screening. In order to assess these and possible further changes to cervical screening practice in the UK, we constructed a mathematical model of cervical HPV infection, cervical intraepithelial neoplasia and invasive cervical cancer, and of UK age-specific screening coverage rates, screening intervals and treatment efficacy. The predicted cumulative lifetime incidence of invasive cervical cancer in the UK is 1.70% in the absence of screening and 0.77% with pre-2003 screening practice. A reduction in lifetime incidence to 0.63% is predicted following the implementation of the 2003 NHSCSP recommendations, which represents a 63% reduction compared to incidence rates in the UK population if it were unscreened. The model suggests that, after the implementation of the 2003 recommendations, increasing the sensitivity of the screening test regime from its current average value of 56 to 90% would further reduce the cumulative lifetime incidence of invasive cervical cancer to 0.46%. Alternatively, extending screening to women aged 65 - 79 years would further reduce the lifetime incidence to 0.56%. Screening women aged 20 - 25 years would have minimal impact, with the cumulative lifetime incidence decreasing from 0.63 to 0.61%. In conclusion, the study supports the 2003 recommendations for changes to cervical screening intervals.
引用
收藏
页码:530 / 536
页数:7
相关论文
共 33 条
[1]  
BARNABAS RV, 2004, IN PRESS EUROPEAN CO
[2]  
BERAL V, 1994, CANCER SURV, V20, P265
[3]  
Bodner K, 2002, ANTICANCER RES, V22, P3733
[4]   Management of women who test positive for high-risk types of human papillomavirus: the HART study [J].
Cuzick, J ;
Szarewski, A ;
Cubie, H ;
Hulman, G ;
Kitchener, H ;
Luesley, D ;
McGoogan, E ;
Menon, U ;
Terry, G ;
Edwards, R ;
Brooks, C ;
Desai, M ;
Gie, C ;
Ho, L ;
Jacobs, I ;
Pickles, C ;
Sasieni, P .
LANCET, 2003, 362 (9399) :1871-1876
[5]  
DEBRUX J, 1983, B CANCER, V70, P410
[6]  
*DEP HLTH, 2001, DEP HLTH B
[7]  
Esteve J, 1994, IARC SCI PUBLICATION, V128
[8]   PERSISTENCE OF TYPE-SPECIFIC HUMAN PAPILLOMAVIRUS INFECTION AMONG CYTOLOGICALLY NORMAL WOMEN [J].
HILDESHEIM, A ;
SCHIFFMAN, MH ;
GRAVITT, PE ;
GLASS, AG ;
GREER, CE ;
ZHANG, T ;
SCOTT, DR ;
RUSH, BB ;
LAWLER, P ;
SHERMAN, ME ;
KURMAN, RJ ;
MANES, MM .
JOURNAL OF INFECTIOUS DISEASES, 1994, 169 (02) :235-240
[9]   Natural history of cervicovaginal papillomavirus infection in young women [J].
Ho, GYF ;
Bierman, R ;
Beardsley, L ;
Chang, CJ ;
Burk, RD .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (07) :423-428
[10]   A COHORT STUDY OF THE RISK OF CERVICAL INTRAEPITHELIAL NEOPLASIA GRADE-2 OR GRADE-3 IN RELATION TO PAPILLOMAVIRUS INFECTION [J].
KOUTSKY, LA ;
HOLMES, KK ;
CRITCHLOW, CW ;
STEVENS, CE ;
PAAVONEN, J ;
BECKMANN, AM ;
DEROUEN, TA ;
GALLOWAY, DA ;
VERNON, D ;
KIVIAT, NB .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (18) :1272-1278